Foresite Capital Fund IV, L.P. - 30 Sep 2025 SCHEDULE 13G/A Report for Lyell Immunopharma, Inc. Common Stock, par value $0.0001 (LYEL)

Filing Manager
Foresite Capital Fund IV, L.P.
Reporting Manager
James B. Tananbaum
Security
Lyell Immunopharma, Inc. Common Stock, par value $0.0001
Symbol
LYEL
Shares outstanding
19,139,684 shares
Disclosed Ownership
1,454,616 shares
Ownership
7.6%
Form type
SCHEDULE 13G/A
Filing time
14 Nov 2025, 16:05:18 UTC
Date of event
30 Sep 2025
SEC
View on sec.gov

Reporting Managers (7)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Foresite Capital Fund IV, L.P. 4.2% 800,339 800,339 0 /s/ James Tananbaum James Tananbaum, Managing Member of the General Partner
Foresite Capital Management IV, LLC 4.2% 800,339 800,339 0 /s/ James Tananbaum James Tananbaum, Managing Member
Foresite Capital Fund V, L.P. 2.5% 477,078 477,078 0 /s/ James Tananbaum James Tananbaum, Managing Member of the General Partner
Foresite Capital Management V, LLC 2.5% 477,078 477,078 0 /s/ James Tananbaum James Tananbaum, Managing Member
Foresite Capital Opportunity Fund V, L.P. 0.9% 177,199 177,199 0 /s/ James Tananbaum James Tananbaum, Managing Member of the General Partner
Foresite Capital Opportunity Management V, LLC 0.9% 177,199 177,199 0 /s/ James Tananbaum James Tananbaum, Managing Member
James B. Tananbaum 7.6% 1,454,616 1,454,616 0 /s/ James Tananbaum James Tananbaum